Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more
Ascelia Pharma AB (publ) - Asset Resilience Ratio
Ascelia Pharma AB (publ) (ACE) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Ascelia Pharma AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ascelia Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ascelia Pharma AB (publ) maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ascelia Pharma AB (publ) Industry Peers by Asset Resilience Ratio
Compare Ascelia Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Ascelia Pharma AB (publ) (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Ascelia Pharma AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | Skr1.00K | Skr87.07 Million | -- |
| 2020-12-31 | 0.00% | Skr0.00 | Skr255.37 Million | -- |
| 2019-12-31 | 30.26% | Skr75.71 Million | Skr250.23 Million | +4.14pp |
| 2018-12-31 | 26.12% | Skr75.08 Million | Skr287.42 Million | +26.18pp |
| 2016-12-31 | -0.06% | Skr-47.00K | Skr80.39 Million | -- |